Suven Pharmaceuticals Ltd
Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]
- Market Cap ₹ 20,043 Cr.
- Current Price ₹ 787
- High / Low ₹ 808 / 471
- Stock P/E 65.8
- Book Value ₹ 80.8
- Dividend Yield 0.13 %
- ROCE 21.1 %
- ROE 16.0 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 26.3%
Cons
- Stock is trading at 9.75 times its book value
- Promoter holding has decreased over last quarter: -9.90%
- Working capital days have increased from 215 days to 401 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 378 | 834 | 1,010 | 1,320 | 1,330 | 1,025 | |
| 206 | 449 | 567 | 738 | 740 | 615 | |
| Operating Profit | 172 | 385 | 443 | 582 | 590 | 410 |
| OPM % | 45% | 46% | 44% | 44% | 44% | 40% |
| 1 | 18 | 14 | 188 | 45 | 55 | |
| Interest | 3 | 22 | 12 | 9 | 13 | 7 |
| Depreciation | 12 | 24 | 32 | 39 | 43 | 49 |
| Profit before tax | 158 | 358 | 414 | 722 | 579 | 409 |
| Tax % | 31% | 24% | 25% | 23% | 25% | 25% |
| 109 | 270 | 309 | 558 | 433 | 305 | |
| EPS in Rs | 5,463.50 | 10.61 | 12.12 | 21.92 | 16.99 | 11.97 |
| Dividend Payout % | 0% | 24% | 16% | 23% | 35% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | 1% |
| TTM: | -23% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 23% |
| 3 Years: | 0% |
| TTM: | -28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| 1 Year: | 61% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 26% |
| Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0 | 13 | 25 | 25 | 25 | 25 |
| Reserves | 578 | 770 | 1,040 | 1,495 | 1,724 | 2,030 |
| 83 | 186 | 143 | 97 | 70 | 65 | |
| 123 | 142 | 151 | 187 | 139 | 120 | |
| Total Liabilities | 783 | 1,111 | 1,359 | 1,805 | 1,958 | 2,241 |
| 271 | 357 | 441 | 534 | 512 | 524 | |
| CWIP | 111 | 102 | 96 | 30 | 165 | 179 |
| Investments | 7 | 276 | 426 | 600 | 710 | 1,085 |
| 394 | 376 | 395 | 641 | 571 | 453 | |
| Total Assets | 783 | 1,111 | 1,359 | 1,805 | 1,958 | 2,241 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 50 | 359 | 329 | 270 | 484 | 371 | |
| -65 | -367 | -258 | -90 | -236 | -382 | |
| 26 | 9 | -76 | -156 | -236 | -14 | |
| Net Cash Flow | 11 | 1 | -4 | 23 | 13 | -25 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 142 | 51 | 37 | 65 | 30 | 45 |
| Inventory Days | 556 | 278 | 243 | 259 | 284 | 266 |
| Days Payable | 190 | 113 | 100 | 97 | 56 | 50 |
| Cash Conversion Cycle | 509 | 217 | 180 | 228 | 258 | 261 |
| Working Capital Days | 285 | 105 | 95 | 126 | 117 | 401 |
| ROCE % | 46% | 39% | 50% | 34% |
Documents
Announcements
- Transcript Of The Conference Call For Acquisition Of A Majority Stake In Sapala Organics 21 Jun
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 21 Jun
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
19 Jun - Read with Para A of Part A of Schedule III of the SEBI (LODR) Regulations, 2015, and with reference to our conference call intimation dated …
- Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011. 19 Jun
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 19 Jun
Annual reports
Concalls
-
Jun 2024Transcript PPT
-
Jun 2024TranscriptPPT
-
Mar 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Dec 2022TranscriptPPT
-
Nov 2022TranscriptPPT
-
Aug 2022Transcript PPT
-
Jun 2022TranscriptPPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Dec 2020TranscriptPPT
-
Oct 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
Business Segments
CDMO (Development projects and Commercial supplies)
SPL engages in NCE molecule development and supply of intermediates. This is a high-value-add, high-margin business. SPL supplies intermediates for four molecules addressing rheumatoid arthritis, diabetes, depression and women’s health[1].The company has a strong order book with new clients being consistently added. Most clients are the Big Pharma companies in Europe and the US. The company is looking to shift from Intermediate to API manufacturing and is in discussion with clients regarding this. The company has stated that it has the facilities for API manufacturing.[2]